1.
A patient in the surgical ICU has been receiving a succinylcholine infusion for 90 minutes during a prolonged operative procedure. Train-of-four monitoring now shows significant fade (T4/T1 ratio approximately 0.4) with post-tetanic facilitation present, in contrast to the earlier pattern of equal twitch depression without fade.
Which of the following best explains this monitoring change and its appropriate management?
A) The TOF fade confirms deepening Phase I depolarizing block; neostigmine 5 mg IV should be administered immediately to reverse it
B) The pattern reflects tachyphylaxis to succinylcholine requiring dose escalation; the infusion rate should be increased by 50%
C) The fade and post-tetanic facilitation are artifactual; leads should be repositioned and monitoring reassessed before any intervention
D) The TOF fade with post-tetanic facilitation indicates Phase II block, which pharmacologically resembles nondepolarizing block; the infusion should be discontinued and spontaneous recovery awaited — neostigmine may offer partial benefit but is unreliable, and sugammadex has no role as succinylcholine is not an aminosteroid
E) The findings confirm Phase I block; edrophonium rather than neostigmine should be used because of its faster onset and more selective NMJ activity
ANSWER: D
Rationale:
The transition from a Phase I pattern (equal depression of all four twitches, no fade, TOF ratio near 1.0) to a Phase II pattern (TOF fade and post-tetanic facilitation) following prolonged succinylcholine infusion is the defining clinical scenario for Phase II block. After large cumulative doses or extended infusion, the block transitions from a depolarizing mechanism to one that pharmacologically mimics nondepolarizing block. The exact molecular mechanism is incompletely understood but involves receptor desensitization and ion channel block.
Management centers on discontinuing the succinylcholine infusion and allowing spontaneous recovery as the drug is hydrolyzed by plasma butyrylcholinesterase. Neostigmine may offer partial reversal in Phase II but is unreliable — it sometimes hastens recovery and sometimes worsens the block. Current practice generally favors spontaneous recovery over pharmacological reversal of Phase II block. Sugammadex has no role as it binds only aminosteroidal NMBs (rocuronium, vecuronium, pancuronium) and has no affinity for succinylcholine or its metabolites. Option C dismisses real monitoring findings as artifactual without clinical justification.
Option A: Option A incorrectly interprets the pattern as Phase I — TOF fade directly contradicts Phase I, which shows no fade.
Option B: Option B confuses the monitoring change with pharmacodynamic tolerance requiring escalation, which would worsen the block.
Option E: Option E is incorrect: edrophonium is not preferred over neostigmine in Phase II, and the core management principle of discontinuing the infusion is omitted.
Option C: Option C is incorrect: the TOF fade and post-tetanic facilitation are not artifactual findings requiring lead repositioning; fade on TOF (decreasing amplitude with each successive twitch) is the characteristic electrophysiological signature of non-depolarizing neuromuscular block; post-tetanic facilitation (increased twitch height after a tetanic stimulus) confirms non-depolarizing block and reflects calcium accumulation at the nerve terminal temporarily compensating for the receptor blockade; these are real and diagnostically important findings that correctly guide clinical management.
2.
A 45-year-old male with a complete C5 spinal cord injury sustained 3 weeks ago requires emergency laparotomy for bowel perforation. He is hemodynamically stable with a serum potassium of 4.2 mEq/L. A physician suggests succinylcholine for rapid sequence intubation because of its fast onset and short duration.
Which of the following best explains the contraindication to succinylcholine in this patient and identifies the preferred RSI alternative?
A) Succinylcholine is contraindicated because spinal cord injury leads to upregulation of extrajunctional fetal-type and alpha-7 nicotinic receptors throughout skeletal muscle beginning within 24–72 hours of injury; at 3 weeks this patient is in the highest-risk window, and succinylcholine-induced depolarization of the expanded receptor population can cause potassium efflux sufficient to trigger cardiac arrest; rocuronium 1.2 mg/kg with sugammadex available for reversal is the preferred RSI alternative
B) Succinylcholine carries a relative contraindication due to risk of bradycardia from unopposed vagal stimulation, but this can be mitigated with atropine pretreatment and the contraindication is not absolute
C) Succinylcholine is contraindicated because spinal cord injury above C3 impairs diaphragmatic function, making rapid-onset paralysis dangerous; rocuronium is preferred because its slower onset allows more time to secure the airway
D) Succinylcholine is contraindicated only in the first 24 hours of spinal cord injury due to stress hormone-induced hypokalemia; at 3 weeks the risk has resolved and succinylcholine can be used safely
E) Succinylcholine is contraindicated because it causes direct myocardial depression through inhibition of cardiac nicotinic receptors, worsened by blunted sympathetic compensation in high spinal cord injury
ANSWER: A
Rationale:
Spinal cord injury is one of the most important established contraindications to succinylcholine. The mechanism is upregulation of extrajunctional nicotinic receptors — specifically fetal-type (alpha-1)2-beta-1-delta-gamma and alpha-7-containing receptors — throughout denervated skeletal muscle. This proliferation begins within 24–72 hours of denervation and peaks within 2–4 weeks of injury. At 3 weeks post-injury, this patient is in the highest-risk window for exaggerated succinylcholine-induced hyperkalemia.
The normal baseline serum potassium of 4.2 mEq/L provides no reassurance — the risk is not from elevated baseline potassium but from the acute efflux triggered when succinylcholine depolarizes the vastly expanded receptor population. A rise of 5–10 mEq/L within minutes can bring potassium to 9–14 mEq/L, precipitating ventricular fibrillation and cardiac arrest. Rocuronium 1.2 mg/kg achieves intubating conditions within 60–75 seconds and is the recommended RSI alternative. The availability of sugammadex 16 mg/kg for immediate reversal eliminates the primary historical safety advantage succinylcholine held in cannot-intubate, cannot-oxygenate scenarios. Option D dangerously inverts the temporal relationship — the risk increases over the first weeks and does not resolve at 3 weeks.
Option B: Option B incorrectly frames the risk as bradycardia rather than hyperkalemia, and atropine pretreatment is irrelevant to the actual contraindication.
Option C: Option C incorrectly ties the contraindication to respiratory mechanics rather than potassium efflux.
Option E: Option E fabricates a cardiac nicotinic receptor inhibition mechanism unrelated to succinylcholine's actual pharmacology.
Option D: Option D is incorrect: succinylcholine is not contraindicated only in the first 24 hours of spinal cord injury with resolution of risk by 3 weeks; the timing of hyperkalemia risk in spinal cord injury is precisely the opposite — the risk is lowest in the first 24 hours (before receptor upregulation occurs) and peaks between approximately 1 week and 6 months after injury; by 3 weeks, the upregulation of extrajunctional nAChRs (which are constitutively open and depolarize readily) is well-established, making succinylcholine administration at 3 weeks potentially life-threatening from hyperkalemia-induced cardiac arrest.
3.
A 32-year-old trauma patient with a normal airway requires RSI for emergent intubation. He has no known allergies, no prior anesthesia history, no burn or denervation injuries, and normal renal and hepatic function. Serum potassium is 3.9 mEq/L. The anesthesiologist is deciding between succinylcholine and rocuronium.
Which of the following most accurately compares these agents for RSI in this patient?
A) Rocuronium at standard dose 0.6 mg/kg produces equivalent intubating conditions to succinylcholine at 1.5 mg/kg within 45 seconds, making them clinically interchangeable in all RSI scenarios
B) Succinylcholine remains the preferred agent when no specific contraindication exists, given its unmatched onset at 1.5 mg/kg (45–60 seconds), ultra-short duration of 8–12 minutes allowing return of spontaneous ventilation in failed airway scenarios, and spontaneous offset without pharmacological reversal; rocuronium at 1.2 mg/kg provides comparable onset but with 60–90 minutes duration requiring sugammadex for rapid reversal if needed
C) Rocuronium is universally preferred over succinylcholine in all RSI scenarios regardless of patient characteristics, and succinylcholine should be considered obsolete given the availability of sugammadex
D) Succinylcholine and rocuronium have identical durations when rocuronium is combined with sugammadex pre-loading, and the choice should be based solely on cost
E) Rocuronium is preferred in this trauma patient specifically because the injury mechanism creates a 24-hour window of extrajunctional receptor upregulation that makes succinylcholine dangerous in the immediate post-injury period
ANSWER: B
Rationale:
The comparison of succinylcholine and rocuronium for RSI reflects an ongoing evidence-informed debate in anesthesia practice. Succinylcholine at 1.5 mg/kg achieves profound NMJ blockade within 45–60 seconds and its duration is limited to 8–12 minutes by plasma butyrylcholinesterase hydrolysis. This ultra-short duration is clinically important in cannot-intubate, cannot-oxygenate scenarios — if intubation fails, spontaneous ventilation returns within minutes without pharmacological reversal.
Rocuronium at 1.2 mg/kg achieves onset times approaching succinylcholine (60–75 seconds) at the cost of substantially longer duration — typically 60–90 minutes for spontaneous recovery. This requires sugammadex 16 mg/kg for rapid reversal in failed airway scenarios, adding cost and requiring preparedness in emergency settings. At standard dosing of 0.6 mg/kg, rocuronium onset is 90–120 seconds — slower than succinylcholine and inadequate for fastest RSI scenarios.
In this patient with no contraindications to succinylcholine, its spontaneous offset preserves the most robust safety margin in a failed airway scenario. Current guidelines from major anesthesia societies do not universally declare rocuronium superior for all RSI indications.
Option A: Option A incorrectly states that standard-dose rocuronium achieves equivalent intubating conditions to succinylcholine — it does not at 0.6 mg/kg.
Option C: Option C overstates the case against succinylcholine and misrepresents current consensus.
Option D: Option D is incorrect — sugammadex pre-loading is not standard practice.
Option E: Option E is incorrect — extrajunctional receptor upregulation requires denervation or sustained immobilization, not acute trauma alone, and does not begin within 24 hours.
4.
A 68-year-old patient with end-stage renal disease and Child-Pugh Class C cirrhosis requires prolonged neuromuscular blockade for mechanical ventilation in the ICU. The intensivist needs a nondepolarizing NMB that will provide reliable blockade with predictable recovery despite combined organ failure.
Which of the following is the most pharmacologically appropriate choice?
A) Vecuronium is safest in combined organ failure because it undergoes exclusive renal elimination, which is preserved even in end-stage renal disease through compensatory tubular secretion
B) Pancuronium is preferred because its long duration reduces dosing frequency and its primary hepatic elimination is unaffected by renal failure
C) Rocuronium is the preferred aminosteroid in this setting because it undergoes exclusive hepatic elimination with no renal contribution, making it entirely safe without dose adjustment
D) Mivacurium is preferred because its butyrylcholinesterase metabolism is entirely independent of hepatic and renal function, providing predictable short duration without accumulation
E) Cisatracurium is the agent of choice because it undergoes organ-independent Hofmann elimination at physiologic pH and temperature; compared with atracurium it generates substantially less laudanosine, which has CNS-stimulant properties, and causes no clinically significant histamine release, making it the safest choice for prolonged infusion in combined hepatic and renal failure
ANSWER: E
Rationale:
In patients with combined hepatic and renal failure, only agents undergoing organ-independent metabolism can be administered without risk of accumulation. Atracurium and cisatracurium are unique in this regard, undergoing Hofmann elimination — spontaneous, non-enzymatic chemical degradation driven by physiologic pH and temperature that does not require hepatic enzymes or renal excretion. The principal degradation products, laudanosine and a monoquaternary acrylate, are subsequently cleared by liver and kidney, but the primary degradation of the parent drug is organ-independent, making the onset and early recovery predictable even in multi-organ failure.
Cisatracurium is strongly preferred over atracurium for prolonged ICU infusion in organ failure for two reasons. First, it is approximately 3–4 times more potent than atracurium on a molar basis, so lower molar doses achieve equivalent block, resulting in substantially less laudanosine generation. Laudanosine is a CNS-stimulant metabolite that, with prolonged atracurium infusion, can accumulate to concentrations associated with seizure activity — a risk essentially eliminated with cisatracurium at standard clinical doses. Second, cisatracurium causes minimal histamine release at clinical doses, whereas atracurium releases histamine in a dose-dependent fashion producing hypotension, bronchospasm, and cutaneous flushing.
Option A: Option A is incorrect — vecuronium has significant renal elimination and its active metabolite 3-desacetylvecuronium accumulates catastrophically in renal failure.
Option B: Option B is incorrect — pancuronium has the highest renal dependence of the aminosteroids (40–70%) and produces prolonged block in renal failure.
Option C: Option C is incorrect — rocuronium has up to 30% renal contribution and reduced clearance in severe cirrhosis.
Option D: Option D is incorrect — mivacurium is metabolized by butyrylcholinesterase, which is synthesized in the liver; Child-Pugh C cirrhosis markedly reduces BChE activity, prolonging mivacurium duration unpredictably and making it unsuitable in this patient.
5.
A patient requires reversal of rocuronium-induced neuromuscular blockade at the end of a 4-hour procedure. Quantitative TOF monitoring shows a TOF count of 1 (only T1 detectable, T2 through T4 absent) with a post-tetanic count of 8. The anesthesiologist must decide between neostigmine and sugammadex.
Which of the following best describes the correct reversal strategy?
A) Neostigmine 5 mg with glycopyrrolate 1 mg can reliably reverse rocuronium at any depth including TOF count of 1 and should be administered now to expedite extubation
B) Sugammadex 2 mg/kg is appropriate because this dose is indicated for moderate blockade, defined by TOF count of at least 1
C) Neostigmine is ineffective at this depth; sugammadex 4 mg/kg is the correct choice, as this dose is specifically indicated for deep blockade defined as TOF count of 1–2 with post-tetanic count present, and will achieve a TOF ratio of 0.9 or greater within approximately 3 minutes
D) Neither agent is appropriate; the team should wait until spontaneous recovery produces TOF count of 4 before administering any reversal agent, as premature reversal increases recurarization risk regardless of agent
E) Sugammadex 16 mg/kg is required because any TOF count less than 4 constitutes profound blockade mandating the highest dose regardless of post-tetanic count findings
ANSWER: C
Rationale:
Depth of neuromuscular block is precisely classified by TOF count and post-tetanic count, and this classification determines the appropriate reversal strategy. Profound block is defined as no TOF response and PTC of 0, requiring sugammadex 16 mg/kg. Deep block is defined as no TOF response with PTC of 1 or greater, or TOF count of 1–2, requiring sugammadex 4 mg/kg. Moderate block is defined as TOF count of 2 or greater, requiring sugammadex 2 mg/kg. This patient has TOF count of 1 with PTC of 8, placing him in the deep block category.
Neostigmine requires adequate spontaneous recovery — typically TOF count of 2 or greater, ideally 4 — to be effective, because its competitive mechanism depends on sufficient unblocked receptors to allow acetylcholine to compete with residual rocuronium. When the block is too deep, neostigmine has insufficient competitive substrate, and administration at this depth produces unreliable and potentially worsened blockade.
Sugammadex 4 mg/kg at deep block reliably achieves complete reversal with TOF ratio of 0.9 or greater within approximately 3 minutes, because encapsulation of rocuronium is not dependent on receptor competition. Following reversal, quantitative confirmation of TOF ratio of at least 0.9 should still be obtained before extubation.
Option A: Option A is incorrect — neostigmine cannot reliably reverse at TOF count of 1.
Option B: Option B is incorrect — sugammadex 2 mg/kg is indicated for moderate block with TOF count of at least 2, not deep block with TOF count of 1.
Option D: Option D is incorrect — waiting for full spontaneous recovery is unnecessary when depth-appropriate sugammadex dosing is available.
Option E: Option E is incorrect — TOF count of 1 with PTC present is deep block requiring 4 mg/kg, not profound block requiring 16 mg/kg.
6.
A 38-year-old woman requests smoking cessation pharmacotherapy. She has a 20 pack-year history and four prior quit attempts using nicotine replacement therapy alone without sustained success. She reports strong cravings triggered by environmental cues and continued smoking during stress even after committing to quit. She has no psychiatric history and takes a combined oral contraceptive pill as her only regular medication.
Which of the following best describes the most pharmacologically appropriate recommendation and key considerations for this patient?
A) Combination NRT with a long-acting patch and short-acting rescue form is the most appropriate next step since prior failures were likely due to monotherapy; no other agent is needed in a patient without psychiatric history
B) Bupropion sustained-release is preferred over varenicline because it has no interaction with oral contraceptives and a longer evidence base; varenicline should be reserved for patients who have failed bupropion
C) All three pharmacological options — NRT, bupropion, and varenicline — are equivalent in efficacy and the choice should be based solely on patient preference and cost
D) Varenicline is absolutely contraindicated in patients taking oral contraceptives due to CYP3A4 induction that reduces contraceptive hormone levels to subtherapeutic concentrations
E) Varenicline is the most pharmacologically appropriate choice given four prior NRT failures; as a partial agonist at (alpha-4)2(beta-2)3 receptors it simultaneously reduces withdrawal craving and blocks nicotine reward, directly addressing the cue-triggered and stress-triggered relapse patterns described; varenicline itself has no pharmacokinetic interaction with oral contraceptives, but if she were to receive sugammadex within 7 days of a surgical procedure, the anesthesia team should know that sugammadex binds progestins with sufficient affinity to reduce hormonal contraceptive efficacy
ANSWER: E
Rationale:
Varenicline is the most pharmacologically appropriate choice for this patient. Four prior NRT failures with persistent cue-triggered and stress-triggered smoking indicate a high degree of neurobiological addiction driven by (alpha-4)2(beta-2)3 nicotinic receptor-mediated dopamine release in the mesolimbic pathway. NRT provides only agonist activity and, as her history demonstrates, does not reliably block the reinforcing effects of breakthrough smoking during cravings or stress. The conditioned dopaminergic responding she describes — smoking in response to environmental cues and stress despite a stated commitment to quit — is precisely the behavior that NRT's pure agonism is insufficient to extinguish.
Varenicline's partial agonist mechanism addresses both dimensions of her challenge: sustained, low-level receptor activation reduces withdrawal craving and background dysphoria, while competitive receptor occupancy blunts the rewarding dopamine surge if she does smoke, reducing reinforcement of relapse behavior. Meta-analyses consistently show varenicline achieves higher sustained abstinence rates than either NRT monotherapy or bupropion.
Regarding medications: varenicline does not induce or inhibit CYP enzymes and has no pharmacokinetic interaction with combined oral contraceptives. The sugammadex-contraceptive interaction is a separate clinical fact worth noting because she may undergo surgery — sugammadex binds progestins with affinity sufficient to impair hormonal contraceptive efficacy, and patients should be counseled to use additional contraceptive protection for 7 days after sugammadex administration.
Option A correctly notes that combination NRT outperforms monotherapy but fails to recognize that four prior NRT failures warrant escalation to a mechanistically distinct agent.
Option B: Option B is incorrect — current evidence supports varenicline as the most effective single agent, not as a second-line option after bupropion.
Option C: Option C is incorrect — varenicline produces higher quit rates than NRT or bupropion as monotherapy; they are not equivalent.
Option D: Option D is incorrect — varenicline does not induce CYP3A4 and has no pharmacokinetic interaction with oral contraceptives.
Option A: Option A is incorrect: combination NRT with a long-acting patch and short-acting rescue form is not the most appropriate next step after four prior NRT failures; while combination NRT is superior to patch monotherapy (correct), four prior NRT failures indicate inadequate response to the NRT mechanism class; escalation to a mechanistically distinct agent (varenicline for α4β2 partial agonism or bupropion for dopamine/NE reuptake inhibition) provides a different pharmacological approach to nicotine addiction that may succeed where NRT has failed.
7.
A patient with schizophrenia smokes 40 cigarettes per day and has refused all prior smoking cessation interventions. The psychiatrist considers whether the heavy smoking reflects more than simple addiction and what pharmacological approaches are most appropriate in this population.
Which of the following best characterizes the relationship between (alpha-7)5 nicotinic receptor function, schizophrenia, and smoking cessation pharmacotherapy in this patient?
A) Heavy smoking in schizophrenia may represent partial self-medication of (alpha-7)5 receptor hypofunction — a deficit associated with impaired auditory sensory gating measured by P50 suppression, working memory dysfunction, and attentional impairment; varenicline is pharmacologically appropriate for smoking cessation in schizophrenia and was not shown to significantly worsen neuropsychiatric outcomes in the EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study) trial, though monitoring remains prudent; bupropion carries a seizure risk requiring caution in patients receiving antipsychotics that also lower seizure threshold
B) The heavy smoking is entirely explained by nicotine addiction at (alpha-4)2(beta-2)3 receptors with no relationship to (alpha-7)5 function; NRT is the only appropriate cessation pharmacotherapy because varenicline is absolutely contraindicated in all patients with psychotic disorders
C) Heavy smoking in schizophrenia is primarily a social behavior related to institutional environments with no neurobiological basis; no pharmacological cessation therapy is appropriate because all available agents worsen psychosis through dopaminergic mechanisms
D) Bupropion is preferred in schizophrenia because it compensates for the dopaminergic deficit of schizophrenia; NRT is contraindicated because nicotine worsens psychosis through mesolimbic dopamine stimulation
E) Schizophrenia is associated with upregulated (alpha-7)5 receptors, and heavy smoking worsens psychosis by providing excessive alpha-7 stimulation; varenicline is contraindicated because its partial agonist activity further destabilizes the hyperactive receptor system
ANSWER: A
Rationale:
The relationship between (alpha-7)5 receptor biology and schizophrenia is well-established. Patients consistently demonstrate reduced (alpha-7)5 receptor expression and function in hippocampus and prefrontal cortex, impaired auditory sensory gating quantified by the P50 suppression paradigm — in which a conditioning auditory stimulus normally suppresses the response to a test stimulus 500 ms later, a filtering function dependent on (alpha-7)5 activity — and deficits in working memory, attention, and executive function that map onto regions of high (alpha-7)5 expression. The prevalence of smoking in schizophrenia (approximately 80–90%) substantially exceeds that of the general population (approximately 20%), and studies showing that nicotine transiently normalizes P50 gating deficits in schizophrenia patients support the self-medication hypothesis.
Regarding smoking cessation pharmacotherapy in schizophrenia: the FDA removed the black box warning for varenicline regarding neuropsychiatric adverse effects in 2016 following the EAGLES trial — a large randomized double-blind study in smokers with and without psychiatric disorders — which found that varenicline did not significantly increase neuropsychiatric adverse events compared with NRT or bupropion in patients with stable psychiatric conditions. Varenicline is now considered appropriate for smoking cessation in schizophrenia with appropriate monitoring. Bupropion lowers the seizure threshold and must be used cautiously alongside antipsychotics that share this effect, particularly clozapine and low-potency phenothiazines.
Option B: Option B incorrectly states that smoking has no (alpha-7)5 basis and incorrectly contraindicates varenicline in all psychotic disorders.
Option C: Option C is incorrect — there is substantial neurobiological evidence for the smoking-schizophrenia relationship, and multiple pharmacological options are appropriate.
Option D: Option D incorrectly frames bupropion as correcting a dopaminergic deficit and incorrectly contraindicates NRT.
Option E: Option E inverts the receptor biology — schizophrenia is associated with (alpha-7)5 hypofunction, not hyperfunction.
8.
A 55-year-old man presents with a 6-month history of proximal muscle weakness that is worse at the beginning of activity but improves after 10–15 minutes of exercise. He also reports dry mouth and erectile dysfunction. Examination reveals hyporeflexia that improves after brief voluntary contraction. Repetitive nerve stimulation at 50 Hz shows a 400% increment in compound muscle action potential amplitude. Chest CT reveals a 2.8 cm hilar mass consistent with small-cell lung cancer.
Which of the following best explains the pathophysiology of this presentation and the pharmacological approach to treatment?
A) This is consistent with myasthenia gravis; the incremental EMG response at 50 Hz is a measurement artifact of the decrement; treatment with pyridostigmine and thymectomy is indicated
B) This presentation is consistent with Lambert-Eaton myasthenic syndrome caused by paraneoplastic autoantibodies against presynaptic P/Q-type voltage-gated calcium channels; treatment of the underlying SCLC (small cell lung cancer) is the priority; symptomatic improvement is achieved with amifampridine (3,4-diaminopyridine), which blocks presynaptic potassium channels and prolongs depolarization to enhance calcium entry and acetylcholine release; pyridostigmine provides modest additive benefit; immunotherapy may also be considered
C) The 400% CMAP (compound muscle action potential) increment at 50 Hz is the characteristic electrophysiological finding of botulinum toxin poisoning, in which botulinum cleaves SNARE (soluble NSF attachment protein receptor) proteins and prevents vesicle fusion; treatment with heptavalent botulinum antitoxin is indicated
D) This represents myotonic dystrophy type 1; the incremental EMG response reflects sodium channel dysfunction characteristic of myotonia; treatment with mexiletine for myotonia and supportive care is indicated
E) This is LEMS (Lambert-Eaton myasthenic syndrome) distinguished from paraneoplastic LEMS by the absence of autonomic features; high-dose pyridostigmine alone produces complete remission in non-paraneoplastic LEMS
ANSWER: B
Rationale:
This presentation is a textbook case of Lambert-Eaton myasthenic syndrome in the paraneoplastic context. Every clinical element is accounted for by LEMS pathophysiology. The proximal weakness that is worst at initiation and improves with sustained activity reflects incremental facilitation of acetylcholine release as intracellular calcium accumulates in presynaptic terminals with repetitive stimulation. The autonomic features — dry mouth from reduced salivary gland parasympathetic transmission and erectile dysfunction from impaired pelvic autonomic ganglionic transmission — reflect the fact that P/Q-type voltage-gated calcium channels targeted by LEMS autoantibodies are expressed not only at the NMJ but also in autonomic nerve terminals. The hyporeflexia that improves post-contraction directly mirrors the incremental EMG response. The 400% increment at 50 Hz repetitive stimulation is the defining electrophysiological hallmark of LEMS, in direct contrast to the decrement seen in myasthenia gravis. The SCLC on CT confirms paraneoplastic origin — SCLC cells express P/Q-type VGCCs as part of their neuroendocrine phenotype, triggering the autoimmune response.
Amifampridine (3,4-diaminopyridine) is the primary symptomatic treatment for LEMS and received FDA approval in 2018. It blocks voltage-gated potassium channels in the presynaptic terminal, prolonging the action potential plateau and thereby extending the window during which calcium channels can open. This increases calcium entry and compensates for the reduced calcium influx caused by VGCC (voltage-gated calcium channel) autoantibody blockade, enhancing acetylcholine vesicle release. Pyridostigmine provides modest additive benefit by reducing acetylcholine breakdown. Immunotherapy (corticosteroids, IVIG [intravenous immunoglobulin], plasma exchange) addresses autoantibody burden and is particularly important alongside oncological treatment of the SCLC.
Option A: Option A is incorrect — the 400% increment is the opposite of MG's characteristic decrement; the two are electrophysiologically opposite and should not be confused.
Option C: Option C is incorrect — while botulism can produce an incremental response through similar presynaptic calcium channel impairment, the combination of paraneoplastic context, autonomic features, and hilar mass on CT points unambiguously to LEMS rather than botulism.
Option D: Option D is incorrect — myotonic dystrophy does not produce the incremental EMG response described here.
Option E: Option E is incorrect — this patient does have autonomic features (dry mouth, erectile dysfunction), and high-dose pyridostigmine alone rarely produces complete remission in any form of LEMS.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.